Medicenna Therapeutics, Inc. — Biomedical Watch V2

Traitements3programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

3

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
MDNA11This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.	Cancer	Phase 1/2	À vérifier	United States, Australia, Canada, Ireland, Portugal, South Korea, Spain, Switzerland	À vérifier
Pembrolizumab (KEYTRUDA®)This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.	Cancer	Phase 1/2	À vérifier	United States, Australia, Canada, Ireland, Portugal, South Korea, Spain, Switzerland	À vérifier
MDNA11This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.	Cancer	Phase 1/2	À vérifier	United States, Australia, Canada, Ireland, Portugal, South Korea, Spain, Switzerland	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
MDNA11	Cancer	Phase 1/2	NCT05086692	ABILITY-1 — A Beta-only IL-2 ImmunoTherapY Study	ACTIVE_NOT_RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.